A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

Trial Identifier: D5181C00001
Sponsor: MedImmune, LLC
Collaborator:
Amgen
NCTID:: NCT02334306
Start Date: June 2015
Primary Completion Date: January 2018
Study Completion Date: August 2018
Condition: Immune, Inflammatory & Infections - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
France Brest Cedex, France, 29609
France LE KREMLIN-BICÊTRE, France, 94275
France Lille Cedex, France, 59037
France Paris, France, 75679
France Paris Cedex 13, France, 75651
France Strasbourg, France, 67098
Sweden Stockholm, Sweden
United Kingdom London, United Kingdom, EC1M 6BQ
United Kingdom Newcastle-upon-Tyne, United Kingdom, NE2 4HH
United Kingdom Swindon, United Kingdom, SN3 6BB
United States of America, CA San Francisco, CA, United States of America, 94143
United States of America, MD Bethesda, MD, United States of America, 20892-1190
United States of America, PA Pittsburgh, PA, United States of America, 15213